CryoPort (CYRX) Competitors $7.27 -0.06 (-0.82%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.27 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYRX vs. JANX, ABCL, EVO, EWTX, ANIP, NTLA, ETNB, VERA, BHVN, and COGTShould you be buying CryoPort stock or one of its competitors? The main competitors of CryoPort include Janux Therapeutics (JANX), AbCellera Biologics (ABCL), Evotec (EVO), Edgewise Therapeutics (EWTX), ANI Pharmaceuticals (ANIP), Intellia Therapeutics (NTLA), 89BIO (ETNB), Vera Therapeutics (VERA), Biohaven (BHVN), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry. CryoPort vs. Its Competitors Janux Therapeutics AbCellera Biologics Evotec Edgewise Therapeutics ANI Pharmaceuticals Intellia Therapeutics 89BIO Vera Therapeutics Biohaven Cogent Biosciences Janux Therapeutics (NASDAQ:JANX) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Which has more volatility and risk, JANX or CYRX? Janux Therapeutics has a beta of 2.86, meaning that its stock price is 186% more volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500. Which has better earnings and valuation, JANX or CYRX? Janux Therapeutics has higher earnings, but lower revenue than CryoPort. Janux Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanux Therapeutics$9.34M149.33-$68.99M-$1.36-17.32CryoPort$228.38M1.60-$114.76M-$2.34-3.11 Do insiders & institutionals have more ownership in JANX or CYRX? 75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 8.1% of Janux Therapeutics shares are owned by insiders. Comparatively, 10.0% of CryoPort shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media refer more to JANX or CYRX? In the previous week, Janux Therapeutics had 2 more articles in the media than CryoPort. MarketBeat recorded 6 mentions for Janux Therapeutics and 4 mentions for CryoPort. Janux Therapeutics' average media sentiment score of 1.42 beat CryoPort's score of 0.75 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Do analysts recommend JANX or CYRX? Janux Therapeutics currently has a consensus target price of $91.89, suggesting a potential upside of 290.02%. CryoPort has a consensus target price of $10.63, suggesting a potential upside of 46.15%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Janux Therapeutics is more favorable than CryoPort.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.08CryoPort 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is JANX or CYRX more profitable? Janux Therapeutics has a net margin of 0.00% compared to CryoPort's net margin of -50.15%. Janux Therapeutics' return on equity of -9.29% beat CryoPort's return on equity.Company Net Margins Return on Equity Return on Assets Janux TherapeuticsN/A -9.29% -8.89% CryoPort -50.15%-11.03%-5.54% SummaryJanux Therapeutics beats CryoPort on 12 of the 17 factors compared between the two stocks. Get CryoPort News Delivered to You Automatically Sign up to receive the latest news and ratings for CYRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYRX vs. The Competition Export to ExcelMetricCryoPortTRANS IndustryTransportation SectorNASDAQ ExchangeMarket Cap$367.51M$5.60B$7.13B$9.53BDividend YieldN/A2.32%706.15%4.08%P/E Ratio-3.1110.4512.9323.80Price / Sales1.601.16527.9588.12Price / CashN/A10.517.6657.96Price / Book0.982.932.065.55Net Income-$114.76M$189.74M$574.24M$259.03M7 Day Performance-7.39%-6.44%-5.20%-4.56%1 Month Performance-2.28%-7.29%-2.14%4.49%1 Year Performance-10.47%-7.33%-2.64%18.05% CryoPort Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYRXCryoPort2.2651 of 5 stars$7.27-0.8%$10.63+46.1%-16.4%$367.51M$228.38M-3.111,186Upcoming EarningsGap DownJANXJanux Therapeutics2.7535 of 5 stars$25.55-1.6%$91.89+259.6%-43.2%$1.54B$10.59M-18.7930Positive NewsUpcoming EarningsABCLAbCellera Biologics2.396 of 5 stars$4.92-3.7%$8.75+77.8%+39.0%$1.52B$28.83M0.00500News CoverageUpcoming EarningsEVOEvotec2.0554 of 5 stars$4.26flat$5.93+39.3%-13.2%$1.51B$862.40M0.004,827News CoverageGap DownEWTXEdgewise Therapeutics2.2753 of 5 stars$14.26+1.0%$40.00+180.5%-14.6%$1.49BN/A-9.2060News CoverageUpcoming EarningsAnalyst ForecastANIPANI Pharmaceuticals3.6381 of 5 stars$66.50-1.5%$78.88+18.6%+0.1%$1.46B$614.38M15.06600Upcoming EarningsNTLAIntellia Therapeutics4.499 of 5 stars$13.11-3.6%$33.37+154.5%-54.3%$1.41B$57.88M0.00600News CoverageGap UpETNB89BIO2.0184 of 5 stars$9.53-0.6%$26.43+177.3%-3.1%$1.40BN/A0.0040Upcoming EarningsAnalyst ForecastVERAVera Therapeutics3.4735 of 5 stars$20.87-4.3%$65.00+211.5%-44.3%$1.39BN/A0.0040News CoveragePositive NewsUpcoming EarningsShort Interest ↑BHVNBiohaven2.3513 of 5 stars$13.10-3.0%$58.46+346.3%-61.3%$1.38BN/A0.00239Trending NewsUpcoming EarningsCOGTCogent Biosciences2.8546 of 5 stars$12.09+0.2%$18.70+54.7%+21.8%$1.37BN/A0.0080Upcoming EarningsGap Up Related Companies and Tools Related Companies Janux Therapeutics Competitors AbCellera Biologics Competitors Evotec Competitors Edgewise Therapeutics Competitors ANI Pharmaceuticals Competitors Intellia Therapeutics Competitors 89BIO Competitors Vera Therapeutics Competitors Biohaven Competitors Cogent Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYRX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CryoPort, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CryoPort With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
